Arcus Biosciences, Inc. (RCUS): who owns it and who trades it
As of Nov 16, 2026, RCUS insiders reported 33 open-market sales worth $10M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Juan C. Jaen (President), with $6.7M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Arcus Biosciences
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RCUS
229 funds and institutions reported RCUS shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Gilead Sciences, Inc. with 25.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 31.42M | 24.99% | $969M | No change |
| BlackRock, Inc. | 16.42M | 13.05% | $506M | +8% |
| State Street Corp | 6.03M | 4.79% | $186M | +11% |
| Wellington Management Group LLP | 5.90M | 4.69% | $182M | -3% |
| Montanova Capital, LLC | 4.78M | 3.80% | $147M | -5% |
| Vanguard Portfolio Management LLC | 4.48M | 3.56% | $138M | +5% |
| FMR LLC (Fidelity) | 4.05M | 3.22% | $125M | +248% |
| Vanguard Capital Management LLC | 3.89M | 3.09% | $120M | +1% |
| Citadel Advisors LLC | 3.14M | 2.49% | $96.7M | +136% |
| Woodline Partners LP | 3.01M | 2.39% | $92.7M | -20% |
| California State Teachers Retirement System | 3.00M | 2.39% | $97.4M | +2739% |
| Geode Capital Management, LLC | 2.45M | 1.95% | $75.5M | +9% |
| Siren, L.L.C. | 2.42M | 1.92% | $74.6M | -20% |
| Fisher Asset Management, LLC | 2.14M | 1.70% | $66M | -2% |
| Marshall Wace, LLP | 1.95M | 1.55% | $60M | -48% |
| Samlyn Capital, LLC | 1.55M | 1.23% | $47.7M | -19% |
| Dimensional Fund Advisors LP | 1.43M | 1.14% | $44.2M | +1% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.42M | 1.13% | $43.8M | -14% |
| Goldman Sachs Group Inc | 1.39M | 1.10% | $42.8M | +39% |
| Soleus Capital Management, L.P. | 1.17M | 0.93% | $36M | +159% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RCUS insiders reported $0 of open-market purchases and $10M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Alexander Azoy | Chief Accounting Officer | Sale plan | 2,827 | $30.00 | $84.8K | Form 4 |
| Jul 10, 2026 | Juan C. Jaen | President | Sale plan | 268 | $29.40 | $7.9K | Form 4 |
| Jul 10, 2026 | Juan C. Jaen | President | Sale plan | 19,799 | $28.61 | $566K | Form 4 |
| Jul 9, 2026 | Juan C. Jaen | President | Sale plan | 48,502 | $30.05 | $1.5M | Form 4 |
| Jun 24, 2026 | Juan C. Jaen | President | Sale | 6,431 | $29.66 | $191K | Form 4 |
| Jun 23, 2026 | Juan C. Jaen | President | Sale | 1,697 | $28.06 | $47.6K | Form 4 |
| Jun 23, 2026 | Juan C. Jaen | President | Sale | 14,067 | $27.69 | $390K | Form 4 |
| Jun 22, 2026 | Juan C. Jaen | President | Sale | 9,236 | $27.03 | $250K | Form 4 |
| Jun 1, 2026 | Alexander Azoy | Chief Accounting Officer | Sale plan | 2,562 | $25.77 | $66K | Form 4 |
| May 11, 2026 | Robert C. Goeltz II | CFO | Sale plan | 7,763 | $25.63 | $199K | Form 4 |
| Jan 5, 2026 | Juan C. Jaen | President | Sale plan | 2,053 | $22.34 | $45.9K | Form 4 |
| Jan 5, 2026 | Juan C. Jaen | President | Sale plan | 29,670 | $21.34 | $633K | Form 4 |
| Jan 5, 2026 | Juan C. Jaen | President | Sale plan | 100 | $23.20 | $2.3K | Form 4 |
| Dec 31, 2025 | Robert C. Goeltz II | CFO | Sale | 6,552 | $23.38 | $153K | Form 4 |
| Dec 18, 2025 | Alexander Azoy | Chief Accounting Officer | Sale plan | 4,343 | $22.25 | $96.6K | Form 4 |
| Dec 17, 2025 | Carolyn C. Tang | General Counsel | Sale plan | 6,810 | $22.16 | $151K | Form 4 |
| Dec 17, 2025 | Richard Markus | Chief Medical Officer | Sale plan | 4,494 | $22.16 | $99.6K | Form 4 |
| Dec 17, 2025 | Alexander Azoy | Chief Accounting Officer | Sale plan | 2,113 | $22.16 | $46.8K | Form 4 |
| Dec 17, 2025 | Robert C. Goeltz II | CFO | Sale plan | 5,960 | $22.16 | $132K | Form 4 |
| Dec 17, 2025 | Jennifer Jarrett | Chief Operating Officer | Sale plan | 9,983 | $22.16 | $221K | Form 4 |
| Dec 17, 2025 | Terry J Rosen | CEO | Sale plan | 25,744 | $22.16 | $570K | Form 4 |
| Dec 16, 2025 | Carolyn C. Tang | General Counsel | Sale plan | 7,658 | $21.88 | $168K | Form 4 |
| Dec 16, 2025 | Richard Markus | Chief Medical Officer | Sale plan | 5,052 | $21.88 | $111K | Form 4 |
| Dec 16, 2025 | Alexander Azoy | Chief Accounting Officer | Sale plan | 2,376 | $21.88 | $52K | Form 4 |
| Dec 16, 2025 | Robert C. Goeltz II | CFO | Sale plan | 6,702 | $21.88 | $147K | Form 4 |
| Dec 16, 2025 | Jennifer Jarrett | Chief Operating Officer | Sale plan | 11,225 | $21.88 | $246K | Form 4 |
| Dec 16, 2025 | Terry J Rosen | CEO | Sale plan | 28,947 | $21.88 | $633K | Form 4 |
| Dec 4, 2025 | Juan C. Jaen | President | Sale plan | 82,997 | $24.71 | $2.1M | Form 4 |
| Nov 26, 2025 | Alexander Azoy | Chief Accounting Officer | Sale plan | 1,900 | $26.00 | $49.4K | Form 4 |
| Nov 26, 2025 | Robert C. Goeltz II | CFO | Sale plan | 5,000 | $25.00 | $125K | Form 4 |
| Nov 18, 2025 | Juan C. Jaen | President | Sale plan | 5,050 | $19.75 | $99.7K | Form 4 |
| Nov 17, 2025 | Juan C. Jaen | President | Sale plan | 37,114 | $20.23 | $751K | Form 4 |
| Nov 17, 2025 | Juan C. Jaen | President | Sale plan | 7,836 | $20.71 | $162K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Juan C. Jaen | President | – | $6.7M | Jul 10, 2026 |
| Terry J Rosen | Chief Executive Officer, Director | – | $1.2M | Dec 17, 2025 |
| Robert C. Goeltz II | Chief Financial Officer | – | $756K | May 11, 2026 |
| Jennifer Jarrett | Chief Operating Officer | – | $467K | Dec 17, 2025 |
| Alexander Azoy | Chief Accounting Officer | – | $396K | Aug 21, 2026 |
| Carolyn C. Tang | General Counsel | – | $318K | Dec 17, 2025 |
| Richard Markus | Chief Medical Officer | – | $210K | Dec 17, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RCUS short interest
Moderate short interest. 9.2% of RCUS shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 13.18M RCUS shares were sold short, 9.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 3.70M shares, buying them all back would take about 3.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.18M | 9.15% | +7% | 3.70M | 3.6 |
| Oct 15, 2026 | 12.36M | 9.71% | -6% | 1.28M | 9.7 |
| Sep 30, 2026 | 13.11M | 10.30% | -5% | 1.72M | 7.6 |
| Sep 15, 2026 | 13.81M | 10.85% | +6% | 1.77M | 7.8 |
| Aug 31, 2026 | 13.08M | 10.27% | -6% | 1.19M | 11.0 |
| Aug 14, 2026 | 13.85M | 10.88% | +6% | 1.13M | 12.3 |
| Jul 31, 2026 | 13.12M | 10.30% | +4% | 1.13M | 11.6 |
| Jul 15, 2026 | 12.56M | 9.99% | -1% | 972,349 | 12.9 |
| Jun 30, 2026 | 12.64M | 10.05% | -5% | 2.14M | 5.9 |
| Jun 15, 2026 | 13.27M | 10.55% | +13% | 1.22M | 10.9 |
| May 29, 2026 | 11.71M | 9.31% | +8% | 929,327 | 12.6 |
| May 15, 2026 | 10.89M | 8.66% | +0% | 970,671 | 11.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Arcus Biosciences company events
Arcus Biosciences filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 23, 2026AnnouncementArcus Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the public offering, issuance and sale of 14,285,715 shares of the Company’s common stock… Filing
- Oct 21, 2026ResultsReleased financial results. Filing
- Oct 20, 2026AnnouncementArcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 20, 2026AnnouncementArcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc., due to futility. Filing
- Mar 23, 2026LeadershipJennifer Jarrett notified Arcus Biosciences, Inc. of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Dec 18, 2025AgreementArcus Biosciences, Inc. entered into a First Amendment to the Loan and Security Agreement with the several banks and other financial institutions or entities party thereto, as lenders, and Hercules Capital, Inc., as administrative agent and collateral agent. Filing
- Dec 12, 2025AnnouncementArcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-221 study due to futility. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arcus Biosciences financials
Famous investors that hold RCUS
6 of the 50 well-known investors we track reported holding RCUS in their latest 13F filing. The largest position is Ken Griffin's, worth $76.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.96M | $76.5M | 0.0% | -6% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1.92M | $49.6M | 0.0% | -10% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 202,458 | $5.2M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 131,221 | $3.4M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 102,500 | $2.6M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 99,037 | $2.6M | 0.0% | -26% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Arcus Biosciences, Inc. (RCUS) stock
Who owns the most RCUS stock?
The largest reported owner of Arcus Biosciences, Inc. (RCUS) is Gilead Sciences, Inc., with 25.0% of the company. In total, 229 funds and institutions reported holding RCUS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RCUS insiders buying or selling?
In the last 12 months, RCUS insiders reported no open-market purchases and 33 sales worth $10M. The latest trade was on Aug 21, 2026. See every trade.
What is the short interest in RCUS?
As of Oct 30, 2026, 13.18M RCUS shares were sold short, 9.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 3.70M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.
Which famous investors hold RCUS?
6 of the 50 well-known investors we track reported RCUS in their latest 13F filing, including Ken Griffin, Ken Fisher, Steve Cohen. The largest position is worth $76.5M. See all holders.
Executive pay
Arcus Biosciences's chief executive was paid a total of $9.7M for the year ended Dec 31, 2025, up 33% from $7.3M the year before. In the last 12 months, Arcus Biosciences's executives and directors bought no stock on the open market and sold $10M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.